AstraZeneca to invest $2.5 billion in Beijing hub as it seeks to move on from China probes
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in the…
61,750€
1,65%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals By Reuters
AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals…
British pharma giant AstraZeneca to invest $2.5 billion in new China hub
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing,…
AstraZeneca to invest $2.5 billion in new Beijing R&D center By Investing.com
AstraZeneca to invest $2.5 billion in new Beijing R&D center…
AstraZeneca investing $2.5 bln in China as drugmaker seeks to recover from scandals
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker…
AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker…
ANGLE passes key milestone as it completes AstraZeneca assay development
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has completed two major projects for AstraZeneca PLC (LSE:AZN), expanding the use of its Parsortix liquid biopsy…
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Astrazeneca (AZN) settling at $76.32, representing a -0.97% change from its previous close.…
Adyen and AstraZeneca gain TD Cowen’s Best Ideas recognition on growth potential By Investing.com
Adyen and AstraZeneca gain TD Cowen’s Best Ideas recognition on growth potential…
AZNs Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer
The European Commission approves AstraZenecas Imfinzi for treating patients with limited-stage small-cell lung cancer based on ADRIATIC study data.…
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies
AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or…
European stocks rise on German debt deal hopes; AstraZeneca in focus By Investing.com
European stocks rise on German debt deal hopes; AstraZeneca in focus…
AstraZeneca to acquire EsoBiotec advance cell therapy platform
AstraZeneca has announced an agreement to acquire EsoBiotec, securing the biotechnology firm’s pioneering in vivo cell therapy platform that has…
AstraZeneca to buy EsoBiotec for up to $1 billion
Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion.…
Prediction: This Vanguard Index Fund Will Continue to Beat the S&P 500 in 2025
The Trump administration has unnerved investors with its departure from traditional trade policy. The average tax on U.S. imports fell…
AstraZeneca Aktie: Performance überzeugt erneut
AstraZeneca befindet sich an einem entscheidenden Punkt, während die Pharmamärkte mit sich entwickelnden wirtschaftlichen Belastungen und veränderter Anlegerstimmung konfrontiert sind.…
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
In the latest trading session, Astrazeneca (AZN) closed at $75.57, marking a +1.79% move from the previous day.…
UBS stuft ASTRAZENECA auf Buy
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Astrazeneca auf "Buy" mit einem Kursziel von 14200…
Director/PDMR Shareholding
7 March 2025
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that, on 6 March 2025, an award of…
AstraZeneca’s Imfinzi success a step towards $80bn revenue aim
AstraZeneca PLC has edged closer to its aim of generating $80 billion in revenue come 2030 on positive results from…